Ferromagnetic Quantum Critical Point Avoided by the Appearance of Another Magnetic Phase in LaCrGe$_3$ under Pressure

Autor: Taufour, Valentin, Kaluarachchi, Udhara S., Khasanov, Rustem, Nguyen, Manh Cuong, Guguchia, Zurab, Biswas, Pabitra Kumar, Bonfá, Pietro, De Renzi, Roberto, Lin, Xiao, Kim, Stella K., Mun, Eun Deok, Kim, Hyunsoo, Furukawa, Yuji, Wang, Cai-Zhuang, Ho, Kai-Ming, Bud'ko, Sergey L., Canfield, Paul C.

Publikováno v: Phys. Rev. Lett. 117 037207 (2016)

The temperature-pressure phase diagram of the ferromagnet LaCrGe$_3$ is determined for the first time from a combination of magnetization, muon-spin-rotation and electrical resistivity measurements. The ferromagnetic phase is suppressed near $2.1$~GP

Externí odkaz: http://arxiv.org/abs/1607.01061

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Praluzatamab Ravtansine, a CD166-Targeting Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial: An Open-Label Phase I/II Trial

Autor: Boni, Valentina, Fidler, Mary J., Arkenau, Hendrik-Tobias, Spira, Alexander, Meric-Bernstam, Funda, Uboha, Nataliya, Sanborn, Rachel E., Sweis, Randy F., LoRusso, Patricia, Nagasaka, Misako, Garcia-Corbacho, Javier, Jalal, Shadia, Harding, James J., Kim, Stella K., Miedema, Iris H. C., Vugts, Danielle J., Huisman, Marc C., Zwezerijnen, Gerben J. C., van Dongen, Guus A. M. S., van Oordt, C. Willemien Menke van der Houven, Wang, Song, Dang, Tam, Zein, Ivan A., Vasiljeva, Olga, Lyman, Susan K., Paton, Virginia, Hannah, Alison, Liu, Joyce F.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, 28(10), 2020-2029. American Association for Cancer Research Inc.
Boni, V, Fidler, M J, Arkenau, H-T, Spira, A, Meric-Bernstam, F, Uboha, N, Sanborn, R E, Sweis, R F, LoRusso, P, Nagasaka, M, Garcia-Corbacho, J, Jalal, S, Harding, J J, Kim, S K, Miedema, I H C, Vugts, D J, Huisman, M C, Zwezerijnen, G J C, van Dongen, G A M S, van Oordt, C W M V D H, Wang, S, Dang, T, Zein, I A, Vasiljeva, O, Lyman, S K, Paton, V, Hannah, A & Liu, J F 2022, ' Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial : An Open-Label Phase I/II Trial ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 10, pp. 2020-2029 . https://doi.org/10.1158/1078-0432.CCR-21-3656, https://doi.org/10.1158/1078-0432.CCR-21-3656

Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::100033410ce9bc7c4138b9e899bc87e6
https://research.vumc.nl/en/publications/d19e2a55-0d4f-4ded-9d53-da033c70ba50

Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report

Autor: Shulman, Howard M., Kleiner, David, Lee, Stephanie J., Morton, Thomas, Pavletic, Steven Z., Farmer, Evan, Moresi, J. Margaret, Greenson, Joel, Janin, Anne, Martin, Paul J., McDonald, George, Flowers, Mary E.D., Turner, Maria, Atkinson, Jane, Lefkowitch, Jay, Washington, M. Kay, Prieto, Victor G., Kim, Stella K., Argenyi, Zsolt, Diwan, A. Hafeez, Rashid, Asif, Hiatt, Kim, Couriel, Dan, Schultz, Kirk, Hymes, Sharon, Vogelsang, Georgia B.

Publikováno v: In Biology of Blood and Marrow Transplantation 2006 12(1):31-47

PHASE 1 TRIALS OF ANTI-ENPP3 ANTIBODY DRUG CONJUGATES IN ADVANCED REFRACTORY RENAL CELL CARCINOMAS

Autor: Thompson, John A., Motzer, Robert J., Molina, Ana M., Choueiri, Toni K., Heath, Elisabeth I., Redman, Bruce G., Sangha, Randeep S., Ernst, D. Scott, Pili, Roberto, Kim, Stella K., Reyno, Leonard, Wiseman, Aya, Trave, Fabio, Anand, Banmeet, Morrison, Karen, Doñate, Fernando, Kollmannsberger, Christian K.

PURPOSE: To determine the safety, pharmacokinetics, and recommended phase 2 dose of an antibody drug conjugate (ADC) targeting ectonucleotide phosphodiesterases-pyrophosphatase 3 (ENPP3) conjugated to monomethyl auristatin F (MMAF) in subjects with a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9a3e5db2e8328b6a6f4f2adeb2f7adab
https://europepmc.org/articles/PMC6731023/